SAN JOSE, Calif., June 28, 2024 /PRNewswire/ — BridGene Biosciences, Inc., a leader in developing covalent small molecule drugs for traditional “hard-to-drug” targets, announced today that the first patient has been dosed in its Phase 1 clinical trial of BGC515, a novel TEAD inhibitor…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.